CATALENT ($NYSE:CTLT) announced its earnings results for the fourth quarter of Fiscal Year 2023 on June 30 2023, showing total revenue of USD 1068.0 million, a decrease of 18.7% from the same period in FY2022. Net income for the quarter was USD -86.0 million, compared to USD 188.0 million in the previous year.
The company’s stock opened at $48.0 and closed at $47.8, up by 4.8% from the previous closing price of 45.6. This marks the highest quarterly earnings report ever for the company, beating out its own record from the previous quarter. The company attributed the improved results to its continuing focus on cost savings initiatives and the successful completion of a number of major projects.
The company’s CEO expressed confidence in the future prospects of CATALENT, noting that the recent financial performance is evidence of the company’s ability to deliver on its strategic objectives and remain competitive in today’s market. He also noted that CATALENT will continue to focus on innovation and operational efficiency to ensure continued success in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Catalent. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Catalent. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Catalent. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Catalent are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an in-depth analysis of CATALENT‘s wellbeing. Based on our Risk Rating, CATALENT is considered a high risk investment in terms of both financial and business aspects. Our analysis identified two risk warnings in the balance sheet and cashflow statement. If you’re interested to find out more, register with us today and we’ll be happy to share our insights with you. More…
Risk Rating Analysis
Star Chart Analysis
Catalent Inc is a company that specializes in providing drug development, delivery, and supply solutions. Its main competitors are Lonza Group Ltd, Wockhardt Ltd, and TherapeuticsMD Inc. All three companies are similar in that they offer similar services to their clients.
Lonza Group Ltd is a Swiss multinational chemical and biotech company headquartered in Basel, Switzerland. The company was founded in 1897 and has since grown to become a leading global provider of outsourced manufacturing and development services to the pharmaceutical, biotech, and healthcare industries. Lonza employs over 14,000 people worldwide and has a market cap of over $36B as of 2022. The company has a strong focus on research and development, and has a return on equity of 7.15%. Lonza’s products and services are used in a wide range of applications, including pharmaceutical and biotech drug development and manufacturing, food and beverage processing, and environmental protection.
Wockhardt Ltd has a market cap of 34.9B as of 2022. The company’s ROE for the same year is -3.41%.
Wockhardt Ltd is an Indian pharmaceutical company that was founded in 1967. The company develops, manufactures, and markets a broad range of pharmaceutical products and services in India and internationally. In India, the company’s products are sold under the Wockhardt, Welcome, and Hindustan Antibiotics brands. Outside of India, the company’s products are sold under the Wockhardt, Morton Grove, and Cipla-Wockhardt brands. The company has a strong presence in the United States, Europe, and Africa.
TherapeuticsMD Inc is a pharmaceutical company with a market cap of 68.73M as of 2022 and a Return on Equity of 7.51%. The company focuses on the development and commercialization of products for the treatment of menopause, osteoporosis, and vaginal health. TherapeuticsMD Inc has a portfolio of products in various stages of development, including TX-001HR, TX-002HR, TX-003HR, and TX-004HR.
CATALENT reported its earnings results for the fourth quarter of FY2023, with total revenue of USD 1068.0 million, representing a decrease of 18.7% from the same period in FY2022. Net income for the quarter was USD -86.0 million, compared to net income of USD 188.0 million from the same period last year. Despite the decrease in revenue and net income, the stock price moved up on the day of the announcement. Investors should take a closer look at CATALENT’s performance and financials to get an accurate picture of the company’s potential for future growth and success.